Bacterin launches a new allograft for orthopedic procedures

Bacterin International Holdings, Inc. (NYSE MKT: BONE) is pleased to announce the launch of OsteoSTX, a new novel allograft for orthopedic procedures. Utilizing Bacterin's proprietary demineralization technology, OsteoSTX are flexible cortical DBM matchsticks designed for multli-level and deformity spinal applications.

"This is the first product Bacterin has launched since I joined the Company, and I have been very pleased with the process and the results," said Dan Goldberger, Bacterin President and CEO. "We introduced this product to key opinion leaders at the NASS Evidence and Technology Spine Summit and the feedback was astounding. I am looking forward to seeing how distribution of this new product will help support our growth goals, and complement our existing product portfolio."

OsteoSTX is the first product in Bacterin's biologic portfolio designed specifically for addressing multi-level spine procedures and deformity cases. Bacterin is the first company to market a product of this type for single use application. The product will be launched this week at the 2014 AAOS Conference in New Orleans, LA, March 12th - 14th. OsteoSTX has already been implanted in patients with strong surgeon feedback supporting the use of the product and the application.